Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial
Calabrò, Luana, MD, Morra, Aldo, MD, Fonsatti, Ester, PhD, Cutaia, Ornella, PhD, Amato, Giovanni, PhD, Giannarelli, Diana, MD, Di Giacomo, Anna Maria, MD, Danielli, Riccardo, MD, Altomonte, Maresa, MD, Mutti, Luciano, MD, Maio, Michele, Dr
Published in The lancet oncology (01.10.2013)
Published in The lancet oncology (01.10.2013)
Get full text
Journal Article
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial
Di Giacomo, Anna Maria, MD, Ascierto, Paolo A, MD, Pilla, Lorenzo, MD, Santinami, Mario, MD, Ferrucci, Pier Francesco, MD, Giannarelli, Diana, PhD, Marasco, Antonella, MD, Rivoltini, Licia, MD, Simeone, Ester, PhD, Nicoletti, Stefania VL, MD, Fonsatti, Ester, PhD, Annesi, Diego, PhD, Queirolo, Paola, MD, Testori, Alessandro, MD, Ridolfi, Ruggero, MD, Parmiani, Giorgio, MD, Maio, Michele, Dr
Published in The lancet oncology (01.09.2012)
Published in The lancet oncology (01.09.2012)
Get full text
Journal Article
Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study
Calabrò, Luana, Morra, Aldo, Fonsatti, Ester, Cutaia, Ornella, Fazio, Carolina, Annesi, Diego, Lenoci, Marica, Amato, Giovanni, Danielli, Riccardo, Altomonte, Maresa, Giannarelli, Diana, Di Giacomo, Anna Maria, Maio, Michele
Published in The lancet respiratory medicine (01.04.2015)
Published in The lancet respiratory medicine (01.04.2015)
Get more information
Journal Article